Hematopoietic Progenitor Cell, Apheresis and Marrow Donor History Questionnaire

The hematopoietic progenitor cell (HPC), Apheresis and HPC, Marrow Donor History Questionnaire (DHQ) materials were developed by the AABB Interorganizational DHQ-HPC Task Force to provide establishments with a standardized tool to screen allogeneic HPC donors for communicable disease risk factors in accordance with requirements of the Food and Drug Administration (FDA), AABB, the Foundation for the Accreditation of Cellular Therapy (FACT), and the National Marrow Donor Program (NMDP).

The FDA does not mandate use of any particular tool to fulfill donor screening requirements for communicable disease risks and has determined that "official" recognition of the HPC, Apheresis and HPC, Marrow DHQ materials in a guidance document is not warranted. The task force believes the DHQ materials, which are harmonized with applicable regulations and guidance documents, will optimize donor comprehension of the questions and provide donor historians with the tools needed to evaluate donor responses. Facilities should read the "User Instructions" carefully before adopting the materials for use.

The task force — which, in addition to AABB, includes an FDA liaison, an ethicist and representatives from the American Association of Tissue Banks, the American Society for Blood and Marrow Transplantation, the American Society for Apheresis, FACT, the International Society for Cellular Therapy, and NMDP – will periodically review the documents to ensure continued compliance with regulatory and accrediting agencies. New questions recommended by the task force or the FDA should be added to the section at the end of the questionnaire designated for additional questions until the DHQ materials can be updated to a new version by the task force. International members may find this area of the DHQ a useful place for any additional eligibility questions required by their national competent authority. Institutions will be notified of any changes as well as the timeline for implementation through existing publications and websites maintained by members of the task force. When a new version of the documents is posted, the previous version will be maintained for a period of time to allow facilities to transition to the new version.

When a facility implements a new version of these DHQ materials, they should follow their established change control process for the incorporation of the new DHQ materials. The change control process should address validation of the use of the new version with other existing processes and appropriate staff training. 

HPC, Apheresis and HPC, Marrow DHQ Version 1.6, December 2016

The HPC, Apheresis and HPC, Marrow Donor History Questionnaire materials have been updated to version 1.6. The revisions made to these documents reflect recommendations made by the FDA’s Guidance for Industry: “Revised Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products Who Have Received Human-Derived Clotting Factor Concentrates,” November 2016. A complete summary of the updates incorporated in this new version is in the chart detailing the changes from version 1.5.

  • Questionnaire, v1.6 PDFWord  
  • Donor Education Materials, v1.6 PDFWord  
  • Medication List, v1.6 PDFWord  
  • User Instructions, v1.6 PDFWord
    • Appendices
      • References PDFWord
      • Flow Charts PDFWord
      • vCJD countries of risk – United Kingdom PDFWord
      • vCJD countries of risk – Europe PDFWord
      • HIV Group O countries of risk – Africa PDFWord
      • Active Zika Virus Transmission Areas PDFWord
    • Chart detailing changes from version 1.5 PDF
Ask FACT

FAQ

Ask a Peer

As a Matter of FACT

FACT was formally known as “FAHCT” (The Foundation for the Accreditation of Hematopoietic Cellular Therapy) until it expanded operations into other cellular therapies beyond hematopoietic cells.

Accreditation Success Story

The Héma-Québec Public Cord Blood Bank (CBB) was created in 2004 to meet the needs of Quebecers and to contribute to the international effort towards a high-quality global inventory of cord blood units. Read more